Given its central role in inflammation and fibrosis, OPN stands out as a promising biomarker for disease progression and a potential therapeutic target for modulating the course of NAFLD and NASH. The gene discussed is SPP1; the disease is metabolic dysfunction-associated steatotic liver disease.